Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Singulair Paediatric 5 mg Chewable Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

One chewable tablet contains montelukast sodium, which is equivalent to 5 mg montelukast.

Excipients with known effect:

This medicinal product contains 1.5 mg aspartame (E 951) per tablet

This medicinal product contains benzyl alcohol (E 1519).

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Chewable tablet

Product imported from Poland:

Pink, round, biconvex, diameter 9.5 mm with SINGULAIR engraved on one side, MSD 275 on the other.

4 CLINICAL PARTICULARS

As per PA23198/014/003

5 PHARMACOLOGICAL PROPERTIES

As per PA23198/014/003

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Mannitol (E 421)

Microcrystalline cellulose

Hyprolose (E 463)

Red ferric oxide (E 172)

Croscarmellose sodium

Cherry flavor (containing benzyl alcohol (E 1519))

Aspartame (E 951)

Magnesium stearate

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

The shelf-life expiry date of this product is the date shown on the blister strips and outer carton of the product on the market in the country of origin.

6.4 Special precautions for storage

Store below 30°C.

Store in the original package in order to protect from light and moisture.

17 July 2023 CRN00DPPN Page 1 of 2

6.5 Nature and contents of container

Aluminium blister strips in an over-labelled cardboard carton containing 28 tablets.

6.6 Special precautions for disposal

Any unused product or waste material should be disposed of in accordance with local requirements.

7 PARALLEL PRODUCT AUTHORISATION HOLDER

IMED Healthcare Ltd. Unit 625 Kilshane Avenue Northwest Business Park Ballycoolin Dublin 15 Ireland

8 PARALLEL PRODUCT AUTHORISATION NUMBER

PPA1463/064/002

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 11th May 2012

10 DATE OF REVISION OF THE TEXT

July 2023

17 July 2023 CRN00DPPN Page 2 of 2